soul trial oral semaglutide cardiovascular outcomes 2024 results nejm Editorial Fellow Harleen Marwah, MD, summarizes the trial. Read the full at NEJM.org (link in bio). ⁣ ⁣ #ACC25 #Cardiology #ClinicalTrials #NEJM Semaglutide reduces heart failure risk

Curcumin modulates critical pathways such as NF-B and downregulates IL-6 and TNF- signaling, leading to improvements in both glucose metabolism and depressive symptoms (Sarmiento-Ortega et al., 2025

That is why this should always start with a qualified healthcare provider who understands your history, your goals, and any factors that could change the plan

MA QUANTA CARNITINA BISOGNA ASSUMERE

Furthermore, before the postnatal age of 10 days, clearance and glucuronidation capacity was approximately 50% lower than thereafter

For a patient with Type 2 diabetes and established heart disease, choosing a GLP-1 agonist over insulin could provide meaningful protection against future cardiovascular events, above and beyond blood sugar control

The protocol is a ceiling, not a mandatory target